Publications
TIL Cells
G-Rex®100M
Publication Date: October 14, 2020
A closed, semi-automatic two-step process using G-Rex® flasks, a Xuri bioreactor and LoVo washing produced clinically sufficient tumor-infiltrating lymphocytes (TILs) in a hospital GMP facility. In 31 paired pre-rapid expansion cultures, G-Rex® 100M flasks gave more TILs than 24-well plates, with equivalent viability and similar CD8+ frequency. After a 7-day G-Rex® step followed by Xuri culture, all 25 rapid expansion runs yielded usable TILs, with a mean of 41.3 × 10^9 viable cells (range 11.0 to 71.5 × 10^9) and an average fold expansion of 1681. Exhaustion marker expression (PD-1, TIM-3) did not differ with the pre-expansion vessel. Final formulation on the LoVo system averaged 90 minu…
Publications
CTL Cells, DC Cells
G-Rex®10
Publication Date: October 9, 2020
Monocyte-derived dendritic cells loaded with a cytomegalovirus peptide and produced in closed fluorinated ethylene propylene (FEP) culture bags activated antigen-specific CD8+ T cells as effectively as cells made in conventional polystyrene plates. Monocytes from healthy donors were differentiated and matured in 1, 2 or 7 mL FEP bags or 24-well polystyrene plates. Surface markers, with CD14 lost and CD80, CD83 and CD86 upregulated, and IL-10 and IL-12 release did not differ significantly between vessels. Autologous T cells (15 × 10^6) were co-cultured for 14 days with NLV-pulsed dendritic cells, and the tetramer-specific CD8+ T cells showed comparable frequency and CD25 activation irrespe…
Publications
Other
G-Rex®6 Well Plate, G-Rex®6M Well Plate
Publication Date: October 1, 2020
CIK cells expanded in G-Rex®6 gas-permeable well plates reached 400-fold expansion in 14 days, giving a mean of 10^9 cells per well from 2.5 × 10^6 starting cells. Cytokine-induced killer cells were generated from healthy donor PBMCs stimulated with GMP-grade IFN-γ, IL-2 and CD3 antibody, then cultured in G-Rex®6 or G-Rex®6M well plates, with fresh IL-2 added every 3–4 days, and compared with standard flasks. In G-Rex®6 the culture was split once at day 7; G-Rex®6M cultures were not adjusted. G-Rex®6 cultures had a higher share of CD3+CD56+ cells and cytotoxicity comparable to standard flasks, whereas G-Rex®6M cells showed markedly lower cytotoxicity against tumor targets, suggesting cell…
Publications
CAR T Cells, NK Cells
G-Rex®6 Well Plate
Publication Date: September 23, 2020
T cells and NK cells engineered with a CAR against CD147 (Basigin) killed hepatocellular carcinoma cells selectively and controlled tumors in mice. CD147 was highly upregulated in HepG2 and SK-Hep1 cells relative to PBMCs, and HCC tissue stained strongly positive compared with healthy liver. CD147-CAR primary T cells, primary NK cells and NK-92MI cells lysed HCC cell lines, with decreased lysis of CD147-knockout lines. In SK-Hep1 xenograft NSG mice, CD147-CAR T and NK cells suppressed tumor growth and prolonged survival, and in a patient-derived xenograft model, median survival with CD147-CAR-NK-92MI cells was 63 days versus about 42 days in controls. A GPC3-synNotch-gated CD147-CAR selec…
Publications
TCR T Cells
G-Rex®10
Publication Date: September 11, 2020
Base editing with a lentiviral vector that carries both an HBV-specific recombinant TCR and a guide RNA against the endogenous TCR beta constant genes removed endogenous TCRs and enriched antigen-specific T cells. After transient delivery of codon-optimized BE3 mRNA and magnetic depletion of residual endogenous TCR-positive cells, products reached over 99% endogenous TCR-negative and 95.9% recombinant TCR-positive in a representative donor. Recombinant TCR surface intensity rose, and edited cells produced more cytokine and killed HepG2 targets faster in impedance and 3D microfluidic assays. Sequencing showed C>T conversion of 37.3% and 24.3% at positions C5 and C6, small and large inde…
Publications
VST Cells
G-Rex®10
Publication Date: September 11, 2020
A 96-well, 13-color flow cytometry screen identified IL-15 plus IL-6 as a cytokine pair that expands cytomegalovirus-specific T cells as well as the standard IL-4 plus IL-7, while skewing products toward CD8+ cells. Using donor PBMCs pulsed with IE1 and pp65 peptide pools, one plate tested 40 cytokine combinations with only 1 × 10^7 cells. After 10 days, IL-15/IL-6 expanded CD3+ cells a median 17.1-fold over no-cytokine controls versus 13.8-fold for IL-4/IL-7; it yielded 2.8-fold more CD8+ cells, whereas IL-4/IL-7 yielded 2.1-fold more CD4+ cells. Median IFN-γ-producing CD3+ cells were 19.3% and 16.3%. In G-Rex® 10 vessels, IL-15/IL-6 cells gave 638 ± 297 IFN-γ ELISpot spots per 100,000 c…
Publications
CAR T Cells
G-Rex®100M
Publication Date: August 4, 2020
ISIKOK-19, an academically manufactured anti-CD19 CAR-T product, was specifically activated by and highly cytotoxic to CD19-positive lymphoma cells in vitro and in NOD/SCID mice. FuGENE transfection gave a lentiviral titer of 17.4 × 10^6, versus 0.44 × 10^6 with PEI. Combining spinoculation, protamine sulfate and Vectofusin-1 raised CAR expression from 18.9% to 67.2% in healthy-donor T cells. In the Raji mouse model, tumor burden fell 15-fold with one CAR-T dose and 75-fold with two, and no CAR-T-treated mouse died during 60 days of follow-up. T cells from 10 relapsed/refractory ALL/NHL patients yielded 4 to 6 × 10^6 CAR-T cells per kilogram, and BX-795 roughly doubled CAR expression.
Publications
Other
Publication Date: July 28, 2020
Fungus-specific T cells can be manufactured within 11 days from healthy donor stem cell apheresis products by selecting CD137-positive cells after fungal lysate stimulation and expanding them in vitro. Selected cells grew from about 0.07 to 0.1 × 10^6 to roughly 103 to 148 × 10^6 over the culture, more than 1000-fold, and were mainly CD4-positive. The process is good manufacturing practice–compliant. Cells made with A terreus and C krusei lysates responded to dendritic cells sharing only one HLA-DR molecule, even with an allele subtype mismatch, though less strongly than with full matching (12.4% and 9.9% versus 35.7% TNF-α-producing CD4 cells). In humanized NSG mice infected with Aspergi…
Publications
CAR T Cells
Publication Date: July 23, 2020
Autologous CD30-specific CAR T cells given after fludarabine-based lymphodepletion produced high and durable response rates in heavily pretreated relapsed or refractory Hodgkin lymphoma. In two parallel phase I/II trials at two US centers, 41 adults received the cells after bendamustine, bendamustine plus fludarabine, or cyclophosphamide plus fludarabine; patients had a median of 7 prior therapies. Among 32 evaluable patients with active disease who received fludarabine-containing regimens, the overall response rate was 72% and 19 (59%) achieved complete response, whereas bendamustine alone produced no objective responses. Cytokine release syndrome occurred in 10 patients, all grade 1, wi…
Publications
T-Cells
Publication Date: July 19, 2020
A conditionally active T cell engager, COBRA, was engineered as a prodrug that binds EGFR on tumor cells but cannot engage CD3 until a matrix metalloproteinase cleaves its linker. Cleavage by MMP9 rearranged the full-length molecule MVC-101 into an active dimer, raising T cell killing potency of HT-29 and LoVo colorectal cells by more than 500-fold compared with a non-cleavable control, with pre-cleaved material reaching sub-picomolar EC50 values. In mice, MVC-101 had a serum half-life of 18 hours. Dosed at 300 μg/kg every three days for seven doses with human T cells, it completely regressed established HT-29 xenografts, whereas the non-cleavable control did not.
Publications
TIL Cells
Publication Date: July 11, 2020
Building and running a GMP facility inside a hospital offers clear advantages for personalized cell therapies such as tumor-infiltrating lymphocyte treatment, but demands careful balancing of regulatory and hospital requirements. Drawing on the authors' experience establishing two facilities at Lausanne University Hospital, the review cites lower cost, rapid supply and proximity to operating rooms as main benefits, with fresh tumor material arriving within a few hours. Closed-system equipment combined with isolators permits several patient batches in a small facility. Principal challenges are quality-system design, compliant infrastructure, facility costs of several million dollars, and s…
Publications
NK Cells
Publication Date: July 10, 2020
Radiomic analysis of nanoparticle contrast-enhanced images detected the effect of cellular immunotherapy aimed at the tumor microenvironment, where conventional tumor measurements did not. In a mouse neuroblastoma xenograft containing human myeloid-derived suppressor cells (MDSCs), NKG2D.ζ-modified NK cells depleted intratumoral MDSCs and lowered vessel density, yet CT-derived tumor volume, attenuation and fractional blood volume did not differ between groups. Of 107 radiomic features, 91 were tested; 10 features from delayed CT, 13 from CT angiography and 5 from T2-weighted MRI separated treated from untreated tumors, mainly GLSZM and GLRLM texture features. The work is preclinical.
No manuscripts match your filters.